Document:

<PAGE>

                                                                    Exhibit 10.1

                            FORRESTER RESEARCH, INC.

                   AMENDED AND RESTATED 1996 STOCK OPTION PLAN
                           FOR NON-EMPLOYEE DIRECTORS

         1. PURPOSE

         The purpose of this Amended and Restated 1996 Stock Option Plan for
Non-Employee Directors (the "Plan") is to advance the interests of Forrester
Research, Inc. (the "Company") by enhancing the ability of the Company to
attract and retain non-employee directors who are in a position to make
significant contributions to the success of the Company and to reward directors
for such contributions through the awarding of options ("Options") to purchase
shares of the Company's common stock (the "Stock").

         2. ADMINISTRATION

         The Plan shall be administered by a committee (the "Committee") of the
Board of Directors (the "Board") of the Company designated by the Board for that
purpose. Unless and until a Committee is appointed the Plan shall be
administered by the entire Board, and references in the Plan to the "Committee"
shall be deemed references to the Board. The Committee shall have authority, not
inconsistent with the express provisions of the Plan, (a) to grant Options in
accordance with the Plan to such directors as are eligible to receive Options;
(b) to prescribe the form or forms of instruments evidencing Options and any
other instruments required under the Plan and to change such forms from time to
time; (c) to adopt, amend and rescind rules and regulations for the
administration of the Plan; and (d) to interpret the Plan and to decide any
questions and settle all controversies and disputes that may arise in connection
with the Plan. Such determinations of the Committee shall be conclusive and
shall bind all parties.

         3. EFFECTIVE DATE AND TERM OF PLAN

         The Plan shall become effective on the date on which the Plan is
approved by the Board of Directors of the Company, subject to approval by the
shareholders of the Company. No Option shall be granted under the Plan after the
completion

                                      -1-
<PAGE>
of ten years from the date on which the Plan was adopted by the Board, but
Options previously granted may extend beyond that date.

         4. SHARES SUBJECT TO THE PLAN

         (a) Number of Shares. Subject to adjustment as provided in Section
4(c), the aggregate number of shares of Stock that may be delivered upon the
exercise of Options granted under the Plan shall be 300,000. If any Option
granted under the Plan terminates without having been exercised in full, the
number of shares of Stock as to which such Option was not exercised shall be
available for future grants within the limits set forth in this Section 4(a).

         (b) Shares to be Delivered. Shares delivered under the Plan shall be
authorized but unissued Stock or, if the Board so decides in its sole
discretion, previously issued Stock acquired by the Company and held in
treasury. No fractional shares of Stock shall be delivered under the Plan.

         (c) Changes in Stock. In the event of a stock dividend, stock split or
combination of shares, recapitalization or other change in the Company's capital
stock, after the effective date of the Plan, the number and kind of shares of
stock or securities of the Company subject to Options then outstanding or
subsequently granted under the Plan, the maximum number of shares or securities
that may be delivered under the Plan, the exercise price, and other relevant
provisions shall be appropriately adjusted by the Committee, whose determination
shall be binding on all persons.

         5. ELIGIBILITY FOR OPTIONS

         Directors eligible to receive Options under the Plan ("Eligible
Directors") shall be those directors who are not employees of the Company or of
any subsidiary of the Company.

                                      -2-
<PAGE>
         6. TERMS AND CONDITIONS OF OPTIONS

         (a) Formula Options.

         On the date that the Company first files a registration statement under
the Securities Act of 1933 covering shares of Stock, each person who has agreed
to serve as a director and who, upon commencing such service, would be an
Eligible Director shall be awarded on such date an Option covering 6,000 shares
of Stock. Each Eligible Director elected for the first time thereafter shall
also be awarded on the date of his or her first election an Option covering
6,000 shares of Stock. In addition, immediately following the annual meeting of
shareholders, each Eligible Director shall be awarded an Option covering 12,500
shares of Stock. The Options awarded under this paragraph (a) are referred to as
"Formula Options."

         (b) Discretionary Options. The Committee shall also have the authority
under this Plan to award Options to purchase Stock to Eligible Directors in such
amounts and on such terms not inconsistent with this Plan as it shall determine
at the time of the award. The Options awarded under this paragraph (b) are
referred to herein as "Discretionary Options."

         (c) Exercise Price. The exercise price of each Formula Option shall be
(i) in the case of Options granted prior to the Company's initial public
offering, the low end of the estimated price range reflected in the registration
statement and (ii) 100% of the fair market value per share of the Stock at the
time the Option is granted. The exercise price of each Discretionary Options
shall be set by the Committee. In no event, however, shall the Option price be
less, in the case of an original issue of authorized stock, than par value per
share. For purposes of this paragraph, the fair market value of a share of Stock
will be the mean between the high and low sale prices as reported on the
principal market on which the Stock is traded or, if no sales are reported, the
fair market value as determined in good faith by the Committee.

         (d) Duration of Options. The latest date on which an Option may be
exercised (the "Final Exercise Date") shall be the date which is ten years from
the date the Option was granted.

                                      -3-
<PAGE>
         (e) Exercise of Options.

         (1)      Each Formula Option shall become exercisable as to one quarter
                  of the shares covered thereby on each anniversary of the date
                  of the grant; provided, however, that the initial Formula
                  Option for 6,000 shares shall become exercisable as to one
                  quarter of the shares on the date of the award (or on the date
                  of Company's initial public offering in the case of such
                  options granted prior to the Company's initial public
                  offering) and as to one quarter of the shares on each of the
                  next three anniversaries of that date. Each Discretionary
                  Option shall become exercisable at such time or times as the
                  Committee shall determine.

         (2)      Any exercise of an Option shall be in writing, signed by the
                  proper person and delivered or mailed to the Company,
                  accompanied by (i) any documentation required by the Committee
                  and (ii) payment in full for the number of shares for which
                  the Option is exercised.

         (3)      If an Option is exercised by the executor or administrator of
                  a deceased director, or by the person or persons to whom the
                  Option has been transferred by the director's will or the
                  applicable laws of descent and distribution, the Company shall
                  be under no obligation to deliver Stock pursuant to such
                  exercise until the Company is satisfied as to the authority of
                  the person or persons exercising the Option.

         (f) Payment for and Delivery of Stock. Stock purchased under the Plan
shall be paid for as follows: (i) in cash or by check (acceptable to the Company
in accordance with guidelines established for this purpose), bank draft or money
order payable to the order of the Company or (ii) if so permitted by the terms
of the Option, (A) through the delivery of shares of Stock (which, in the case
of shares of Stock acquired from the Company, have been outstanding for at least
six months) having a fair market value on the last business day preceding the
date of exercise equal to the purchase price or (B) by having the Company hold
back from the shares transferred upon exercise Stock having a fair market value
on the last business day preceding the date of exercise equal to the purchase
price or (C) by delivery of a promissory note of the Option holder to the
Company, such note to be payable on such terms as are specified or (D) by
delivery of an unconditional and irrevocable undertaking by a broker to deliver
promptly to the Company

                                      -4-
<PAGE>
sufficient funds to pay the exercise price or (E) by any combination of the
permissible forms of payment; provided, that if the Stock delivered upon
exercise of the Option is an original issue of authorized Stock, at least so
much of the exercise price as represents the par value of such Stock shall be
paid other than with a personal check or promissory note of the Option holder.

         An Option holder shall not have the rights of a shareholder with regard
to awards under the Plan except as to Stock actually received by him or her
under the Plan.

         The Company shall not be obligated to deliver any shares of Stock (a)
until, in the opinion of the Company's counsel, all applicable federal and state
laws and regulations have been complied with, and (b) if the outstanding Stock
is at the time listed on any stock exchange, until the shares to be delivered
have been listed or authorized to be listed on such exchange upon official
notice of issuance, and (c) until all other legal matters in connection with the
issuance and delivery of such shares have been approved by the Company's
counsel. If the sale of Stock has not been registered under the Securities Act
of 1933, as amended, the Company may require, as a condition to exercise of the
Option, such representations or agreements as counsel for the Company may
consider appropriate to avoid violation of such Act and may require that the
certificates evidencing such Stock bear an appropriate legend restricting
transfer.

         (g) Nontransferability of Options. Except as the Committee shall
otherwise provide, no Option may be transferred other than by will or by the
laws of descent and distribution, and during a director's lifetime an Option may
be exercised only by him or her.

         (h) Death. Except as the Committee shall otherwise provided, upon the
death of any director granted Options under this Plan, all Options not then
exercisable shall terminate. All Options held by the director that are
exercisable immediately prior to death may be exercised by his or her executor
or administrator, or by the person or persons to whom the Option is transferred
by will or the applicable laws of descent and distribution, at any time within
one year after the director's death (subject, however, to the limitations of
Section 6(d) regarding the maximum exercise period for such Option). After
completion of that one-year period, such Options shall terminate to the extent
not previously exercised.

         (i) Other Termination of Status of Director. Except as the Committee
shall otherwise provided, if a director's service with the Company terminates
for any

                                      -5-
<PAGE>
reason other than death, all Options held by the director that are not then
exercisable shall terminate. Options that are exercisable on the date of
termination shall continue to be exercisable for a period of three months
(subject to Section 6(d)). After completion of that three-month period, such
Options shall terminate to the extent not previously exercised, expired or
terminated.

         (j) Mergers, etc. In the event of a consolidation or merger in which
the Company is not the surviving corporation (other than a consolidation or
merger in which the holders of Stock of the Company acquire a majority of the
voting stock of the surviving corporation) or which results in the acquisition
of substantially all the Company's outstanding Stock by a single person or
entity or by a group of persons and/or entities acting in concert, or in the
event of a sale or transfer of substantially all of the Company's assets or a
dissolution or liquidation of the Company, all Options hereunder will terminate;
provided, that 20 days prior to the effective date of any such merger,
consolidation, sale, dissolution, or liquidation, all Options outstanding
hereunder that are not otherwise exercisable shall become immediately
exercisable. Notwithstanding the foregoing, in the event that a transaction
covered by this Section 6(j) is a merger or consolidation intended to qualify as
a pooling of interests for accounting purposes, then the acquiring or surviving
corporation shall assume, or otherwise provide replacement options for, all
Options outstanding under this Plan, with such adjustments to the number of
shares covered by such Option and the exercise price thereof as may be necessary
to reflect the exchange ratio provided for in the merger or consolidation. Such
substitute options shall otherwise be on terms and conditions substantially
equivalent to those set forth in this Plan, shall be immediately exercisable
and, except as to Eligible Directors who become directors of the acquiring or
surviving corporation, shall terminate on the 180th day following the
consummation of the merger or consolidation. Options held by Eligible Directors
who become directors of the acquiring or surviving corporation shall be
governed, mutatis mutandis, by the provisions of this Plan and the agreement
evidencing the Option surrendered in substitution.

         7. EFFECT, DISCONTINUANCE, CANCELLATION, AMENDMENT, TERMINATION AND
            EFFECTIVENESS

         Neither adoption of the Plan nor the grant of Options to a director
shall affect the Company's right to grant to such director Options that are not
subject to the Plan, to issue to such directors Stock as a bonus or otherwise,
or to adopt other plans or arrangements under which Stock may be issued to
directors.

                                      -6-<PAGE>
                                                                    EXHIBIT 10.3
AMAGEN

                                          FREESTANDING DIALYSIS CENTER AGREEMENT
--------------------------------------------------------------------------------
     This Agreement ("Agreement"), between Amgen USA Inc. ("Amgen") and National
Medical Care, Inc. including all subsidiaries and affiliates that are at least
fifty and one-tenth percent (50.10%) owned by National Medical Care, Inc. and
listed on Appendix B (collectively, "NMC"), sets forth the terms and conditions
for the purchase of EPOGEN(R) (Epoetin alfa) and Aranesp(TM) (darbepoetin alfa)
(collectively, "Products") by NMC, exclusively for the treatment of dialysis
patients.

1.   TERM OF AGREEMENT. The "Term" of this Agreement shall be defined as January
     1, 2002 ("Commencement Date") through December 31, 2003 ("Termination
     Date").

2.   QUALIFIED PURCHASES. All terms contained herein apply only to purchases
     made hereunder, as confirmed by Amgen ("Qualified Purchases"), by NMC and,
     subject to the terms of Section 11, all Affiliates (as such term is defined
     in Section 11 below) opened, acquired, or managed by NMC during the Term,
     for so long as such Affiliates remain at least fifty and one-tenth percent
     (50.10%) owned or managed by National Medical Care, Inc., through
     wholesalers chosen by NMC and authorized by Amgen to participate in the
     program ("Authorized Wholesalers") or directly from Amgen. In addition, and
     also subject to the terms of Section 11, Renaissance Health Care, Inc.,
     Optimal Renal Care, L.L.C., Integrated Renal Care of the Pacific, and/or
     any joint venture of NMC in which NMC holds at least a fifty and one-tenth
     percent (50.10%) ownership interest, will also be eligible to participate,
     although not required to purchase under this Agreement. Amgen agrees to
     reasonably approve Authorized Wholesalers requested by NMC. The option to
     purchase on a direct basis from Amgen is subject to receipt and approval,
     not to be unreasonably withheld, of an "Application for Direct Ship
     Account".

3.   PRICING. See Appendix A.

4.   PAYMENT TERMS. The terms and conditions of this Agreement shall apply
     whether NMC and/or Affiliates purchase Products through an Authorized
     Wholesaler or from Amgen directly.

5.   DISCOUNT. Amgen will pay discounts and incentives in accordance with the
     schedule and terms set forth in Appendix A attached hereto.

6.   PAYMENT OF DISCOUNTS. Any discount (hereinafter defined as including a
     discount at time of purchase, rebate, incentive or other concession
     impacting the total pricing of a Product) earned hereunder which is
     applicable to purchases of EPOGEN(R) shall be calculated in accordance with
     this Agreement, based on Qualified Purchases, using [*] as the basis for
     the calculation price, and shall be paid in the form of a [*] to National
     Medical Care Inc.'s corporate headquarters, except as otherwise provided
     hereunder. Any discount earned hereunder which is applicable to purchases
     of Aranesp(TM) used to treat dialysis patients shall be calculated in
     accordance with this Agreement, based on Qualified Purchases, using [*] as
     the basis for the calculation price. NMC and Affiliates shall make
     available to Amgen any records concerning NMC's and Affiliates' purchase
     amounts that Amgen or its auditors may reasonably request for purposes of
     verifying discounts. [*]. In the event of a discrepancy between data
     provided by NMC and that provided by an Authorized Wholesaler, verifiable
     data submitted by NMC shall be used. Amgen will use its best efforts to
     make any discount (excluding discounts at time of purchase) pursuant to
     this Agreement available in accordance with the terms referenced in
     Appendix A. Availability of discounts is contingent upon Amgen receiving
     all relevant purchase data from all Authorized Wholesalers designated by
     NMC, in a form reasonably acceptable to Amgen, detailing NMC's and
     Affiliates' Qualified Purchases of Products for the relevant period, along
     with any other data required by the terms of Appendix A. In the event of
     any purchases directly from Amgen, all such purchase data shall be included
     in the calculation of all discounts. In no event shall Amgen pay any
     discount on Products distributed by NMC or Affiliates to non-Affiliates of
     NMC. In the event that Amgen is notified in writing that National Medical
     Care, Inc. and/or any of its subsidiaries or Affiliates (the "Acquiree") is
     acquired by another entity or a change of control otherwise occurs with
     respect to the Acquiree, any discount or rebate which may have been earned
     and vested hereunder prior to the effective date of the acquisition shall
     be paid in the form of a [*] to National Medical Care Inc.'s corporate
     headquarters subject to the conditions described herein.

7.   TREATMENT OF DISCOUNTS. The parties agree that they will account for any
     discount or rebate earned hereunder in a way that complies with all
     applicable federal, state, and local laws and regulations, including
     without limitation, Section 1128B(b) of the Social Security Act and its
     implementing regulations, and if required by such statutes or regulations
     (a) claim the benefit of such discount received, in whatever form, in the
     fiscal year in which such discount was earned or the year after, (b) fully
     and accurately report the value of such discount in any cost reports filed
     under Title XVIII or Title XIX of the Social Security Act, or

                                     - 1 -
<PAGE>
                     FREESTANDING DIALYSIS CENTER AGREEMENT
--------------------------------------------------------------------------------

     a state health care program, and (c) provide, upon request by the U.S.
     Department of Health and Human Services or a state agency or any other
     federally funded state health care program, the information furnished by
     Amgen concerning the amount or value of such discount. NMC agrees that it
     will advise all Affiliates, in writing, of any discount received by
     National Medical Care's corporate headquarters hereunder with respect to
     purchases made by such Affiliates and that NMC will advise said Affiliates
     as to their requirement to account for any such discount in accordance with
     the above stated requirements.

8.   COMMITMENT TO PURCHASE. NMC and Affiliates agrees to purchase EPOGEN(R) for
     all of its dialysis use requirements in the United States, Puerto Rico and
     Guam for recombinant human erythropoietin. Amgen agrees to make such
     EPOGEN(R) available to NMC and Affiliates through its Authorized
     Wholesalers or directly from Amgen. In addition to other remedies available
     to NMC and Affiliates, NMC and Affiliates may purchase another brand of
     recombinant human erythropoietin for its dialysis use requirements in the
     United States, Puerto Rico and Guam if, and only if, NMC and/or any
     Affiliates have informed Amgen, in writing, that NMC and Affiliates are
     unable to acquire sufficient amounts of EPOGEN(R) to meet NMC's and
     Affiliates' reasonable dialysis use requirements, and Amgen by itself, or
     through its Authorized Wholesalers, is actually unable to supply NMC and
     Affiliates with their reasonable dialysis use requirements of EPOGEN(R)
     within the time period reasonably required by NMC and Affiliates, which, in
     no event will be less than five (5) business days after Amgen's receipt of
     NMC's and Affiliates' written notice. If the preceding requirements are
     met, NMC and Affiliates will only be allowed to purchase another brand of
     recombinant human erythropoietin for the time period, and to the extent,
     that Amgen is unable to provide NMC and Affiliates with EPOGEN(R) to meet
     NMC's and Affiliates' reasonable dialysis use requirements.

9.   OWN USE. NMC hereby certifies that Products purchased hereunder will be for
     the "own use" by NMC and the Affiliates of NMC. NMC hereby further
     certifies that all of the Products purchased hereunder shall be for the
     exclusive use of treating dialysis patients.

10.  AUTHORIZED WHOLESALERS. A complete list of NMC's and Affiliates' current
     Authorized Wholesalers, through which NMC and Affiliates may purchase
     Products hereunder is attached as Appendix C. NMC and Affiliates agree to
     promptly provide Amgen with any additions, deletions, or changes to the
     initial list of Authorized Wholesalers. Amgen requires no less than 30 days
     notice before the effective date of change for any addition or deletion of
     Authorized Wholesalers hereunder. Any proposed changes to the initial list
     of Authorized Wholesalers must be in writing and are subject to reasonable
     approval by Amgen.

11.  SUBSIDIARIES AND AFFILIATES. Within thirty (30) days of execution of this
     Agreement, NMC shall provide a current listing of all affiliates, and other
     entities, that will be participating in this Agreement, designating which
     affiliates are owned and/or managed by NMC. Affiliates so designated by NMC
     and approved by Amgen will be deemed "Affiliates" for the purposes of this
     Agreement. Subsequent to approval and acceptance by Amgen, a list of
     Affiliates shall be

     attached to this Agreement as Appendix B and incorporated herein. Only
     those Affiliates approved by Amgen and referenced in Appendix B will be
     eligible to participate under this Agreement. Any NMC managed Affiliate, or
     other entity with an existing contract, may participate in either their
     existing agreement with Amgen, or this Agreement, but not both. Each
     managed Affiliate or entity must declare under which single Amgen contract
     it will participate. Only Qualified Purchases under this Agreement will be
     used in the calculation of pricing, discounts or other incentives under
     this Agreement. NMC will notify Amgen of changes to Appendix B, and the
     effective date of change. Such effective date of change may not be earlier
     than the date the notice is received by Amgen. Any proposed change to
     Appendix B will be subject to the reasonable approval of Amgen based upon
     Amgen's then current legal and contractual requirements, and such proposed
     affiliate's classification as a freestanding dialysis center or a home
     dialysis support facility.

12.  TERMINATION. If either party materially breaches this Agreement, then the
     other party may terminate this Agreement upon thirty (30) days advance
     written notice. In the event that NMC materially breaches any provision of
     this Agreement, Amgen shall have no obligation to continue to offer the
     terms described herein or pay any further unvested discounts to NMC. [*].
     [*].

13.  CONFIDENTIALITY. Both Amgen and NMC agree that this Agreement represents
     and contains confidential information which will not be disclosed to any
     third party, or otherwise made public, without prior written authorization
     of the other party, except where such disclosure is contemplated hereunder
     or required by law or court order. In the event NMC believes it is
     obligated to disclose any such information as required by law or court
     order, NMC will provide Amgen with prior written notice and an
     opportunity to seek a protective order and NMC shall furnish only that
     portion of the information that its counsel advises is required to be
     disclosed by law.

                                     - 2 -
<PAGE>
                     FREESTANDING DIALYSIS CENTER AGREEMENT
--------------------------------------------------------------------------------

14.  WARRANTIES. Each party represents and warrants to the other that this
     Agreement (a) has been duly authorized, executed, and delivered by it, (b)
     constitutes a valid, legal, and binding agreement enforceable against it in
     accordance with the terms contained herein, and (c) does not conflict with
     or violate any of its other contractual obligations, expressed or implied,
     to which it is a party or by which it may be bound. NMC represents and
     warrants that it has the power to bind National Medical Care, Inc. and the
     subsidiaries and owned Affiliates listed on Appendix B to the terms
     contained herein. NMC shall cause each managed Affiliate to be bound by the
     terms and conditions of this Agreement through the execution of a joinder
     agreement executed between NMC and each such managed Affiliate.

15.  GOVERNING LAW. This Agreement will be governed by the laws of the State of
     Delaware and the parties submit to the jurisdiction of Delaware courts,
     both state and federal.

16.  NOTICES. Any notice or other communication required or permitted hereunder
     will be in writing and shall be deemed given or made when delivered in
     person or when received by the other party sent by U.S. Mail, return
     receipt requested, at the respective party's address set forth below or at
     such other address as the party shall have furnished to the other in
     accordance with this provision.

17.  COMPLIANCE WITH HEALTH CARE PRICING AND PATIENT PRIVACY LEGISLATION AND
     STATUTES. a) Notwithstanding anything contained herein to the contrary, at
     any time following the enactment of any federal, state, or local law or
     regulation that materially reforms, modifies, alters, restricts, or
     otherwise affects the pricing of or reimbursement available for any of the
     Products, including a reimbursement or use decision by Centers for Medicare
     and Medicaid Services ("CMS"), either party may initiate good faith
     negotiations to modify this Agreement. If the parties, after 30 days, are
     unable to agree upon such a modification (i) either party may terminate
     this Agreement immediately, or (ii) Amgen may exclude any owned or managed
     Affiliates from participating in this

     Agreement unless such owned or managed Affiliate(s) certifies in writing
     that they are, or will be, exempt from the provisions of such enacted law
     or regulation. Additionally, in order to assure compliance with any
     existing federal, state or local statute, regulation or ordinance, Amgen
     reserves the right, in its reasonable discretion, to exclude any owned or
     managed Affiliates from the pricing, discount, and incentive provisions of
     this Agreement. In the event there is a future change in Medicare,
     Medicaid, or other federal or state statutes or regulations or in the
     interpretation thereof, which renders any of the material terms of this
     Agreement unlawful or unenforceable, this Agreement shall continue only if
     amended by the parties as a result of good faith negotiations as necessary
     to bring the Agreement into compliance with such statute and regulation.

     b) Notwithstanding anything contained herein to the contrary, in order to
     assure compliance, as determined by either party in its reasonable
     discretion, with any existing federal, state or local statute, regulation
     or ordinance relating to patient privacy of medical records, or at any time
     following the enactment of any federal, state, or local law or regulation
     relating to patient privacy of medical records that in any manner reforms,
     modifies, alters, restricts, or otherwise affects any of the data received
     or to be received in connection with any of the incentives contemplated
     under this Agreement, either party may upon thirty (30) days' notice, seek
     to modify this Agreement. NMC and Amgen shall meet and in good faith seek
     to mutually agree to modify this Agreement to accommodate any such change
     in law or regulation, [*]. If the parties in good faith determine that such
     modification is not possible, the parties shall seek to modify the
     Agreement in another manner acceptable to both parties. If the parties,
     after a reasonable time, are unable to agree upon such a modification,
     Amgen shall be entitled to terminate the affected incentive upon thirty
     (30) days' notice or upon the date such change in law or regulation goes
     into effect, whichever is earlier. [*].

18.  INSURANCE AND INDEMNITY. During the Term of this Agreement, Amgen shall
     insure coverage of its obligations hereunder consistent with Amgen
     corporate policy through such programs of self-insurance and/or policies of
     general liability insurance through third-party carriers as Amgen shall
     determine in its sole discretion. Amgen agrees to indemnify, defend and
     hold harmless NMC and its respective employees, officers and directors from
     and against any and all liabilities, losses, claims, or costs, including
     reasonable attorneys' fees, which result directly from Direct Product (as
     such term is defined in Section 20 herein) which as of the date of shipment
     by Amgen: (i) contain defects in material and workmanship, (ii) are
     adulterated or misbranded within the meaning of applicable provisions of
     the Federal Food, Drug and Cosmetic Act (the "FDC Act"), or (iii) are
     prohibited from being introduced into interstate commerce by Section 301 of
     the FDC Act or Section 351 of the Public Health Service Act; provided that
     such indemnity shall not apply to claims arising out of the negligent or
     willful actions or omissions of NMC or its agents, employees,
     representatives, successors or assigns or due to defects in the Direct
     Product caused by persons other than Amgen which

                                     - 3 -
<PAGE>
                     FREESTANDING DIALYSIS CENTER AGREEMENT
--------------------------------------------------------------------------------

     result from neglect, misuse, unauthorized adulteration or modification,
     improper testing, handling or storage or any cause beyond the range of
     normal usage; and further provided that (a) Amgen is promptly notified in
     writing of any such claim, (b) Amgen shall have sole control of the defense
     and settlement thereof, and (c) NMC cooperates fully and gives Amgen all
     requested information and assistance for such defense. Notwithstanding the
     foregoing, Amgen shall not be liable for loss of profit or loss of use,
     incidental or consequential damages arising out of any claim asserted by
     NMC under this Agreement or otherwise. The preceding paragraph sets forth
     NMC's sole remedy for claims of Product defect, adulteration or
     misbranding.

19.  MISCELLANEOUS. No modification of this Agreement shall be effective unless
     made in writing and signed by a duly authorized representative of each
     party. This Agreement constitutes the entire agreement of the parties
     pertaining to the subject matter hereof and supersedes all prior written
     and oral agreements and understandings pertaining hereto including without
     limitation, any previous or existing contract or amendment for the purchase
     of Products for use in the treatment of dialysis patients. Neither party
     shall have the right to assign this Agreement to a third party without the
     prior written consent of the other party provided, however, that Amgen may
     assign this Agreement to any of its subsidiaries or affiliates without the
     written consent of NMC. Neither party shall be liable for delays in
     performance and nonperformance of this Agreement or any covenant contained
     herein caused by fire, flood, storm, earthquake or other act of God, war,
     terrorist acts, rebellion, riot, failure of carriers to furnish
     transportation, strike, lockout or other labor disturbances, act of
     government authority, inability to obtain material or equipment, or any
     other cause of like or different nature beyond the control of such party.
     However, during any time of nonperformance by Amgen which involves NMC's
     and Affiliates' inability to obtain sufficient Products to meet NMC's and
     Affiliates' reasonable dialysis use requirements, the [*] for such
     nonperformance, [*] and NMC and Affiliates may purchase Products from
     another supplier. The parties shall execute and deliver all documents,
     provide all information, and take or refrain from taking action as may be
     necessary or appropriate to achieve the purposes of this Agreement. This
     Agreement may be executed in one or more counterparts, each of which is
     deemed to be an original but all of which taken together constitutes one
     and the same agreement. Amgen reserves the right to rescind this offer if
     the parties fail to execute this Agreement within thirty (30) days from the
     date of its offering.

20.  DIRECT PURCHASE OF PRODUCTS. NMC may purchase EPOGEN(R) M20, 20,000U, 1mL
     vials, NDC 55513-478-10 packaged as ten (10) vials per pack and four (4)
     packs per case and Aranesp(TM) 25 mcg, 1.0 mL vials, NDC 55513-010-04
     packaged as four (4) vials per pack and ten (10) packs per case, 40 mcg,
     1.0 mL vials, NDC 55513-011-04 packaged as four (4) vials per pack and ten
     (10) packs per case, 60 mcg, 1.0 mL vials, NDC 55513-012-04 packaged as
     four (4) vials per pack and ten (10) packs per case, 100 mcg, 1.0 mL vials,
     NDC 55513-013-04 packaged as four (4) vials per pack and ten (10) packs per
     case, and 200 mcg, 1.0 mL vials, NDC 55513-011-04 packaged as one (1) vial
     per pack and four (4) packs per case, (the "Direct Product") on a direct
     basis from Amgen in accordance with the terms set forth under Appendix D
     which is incorporated herein by reference.

     Please retain one fully executed original for your records and return the
     other fully executed original to Amgen.

     THE PARTIES EXECUTED THIS AMENDMENT AS OF THE DATES SET FORTH BELOW.

<TABLE>
<CAPTION>

<S>                                                           <C>
     AMGEN USA INC.                                          NATIONAL MEDICAL CARE, INC.

     Signature:     /s/ Michael Narachi                      Signature:    /s/ Ben Lipps
                    ---------------------------------                      ------------------------------
     Print Name:    Michael Narachi                          Print Name:   Ben Lipps
                    ---------------------------------                      ------------------------------
     Print Title:  Vice President and General Manager        Print Title:  President
                   ----------------------------------                      ------------------------------
     Date:         February 14, 2002                         Date:
                   ----------------------------------                      ------------------------------
</TABLE>

                                     - 4 -
<PAGE>

                     FREESTANDING DIALYSIS CENTER AGREEMENT
--------------------------------------------------------------------------------

                APPENDIX A: DISCOUNT PRICING, SCHEDULE, AND TERMS

1.   PRICING - ARANESP(TM). NMC and Affiliates may purchase Aranesp(TM)through
     Authorized Wholesalers [*]. [*]. [*].

2.   PRICING - EPOGEN(R). NMC and Affiliates may purchase EPOGEN(R) directly
     from Amgen or through Authorized Wholesalers [*] during the period from the
     Commencement Date through December 31, 2002 ("CY1"). NMC and Affiliates may
     purchase EPOGEN(R) directly from Amgen or through Authorized Wholesalers
     [*] during the period from January 1, 2003 through December 31, 2003
     ("CY2"). [*]. [*].

3.   BASE SALES FOR 2001. For purposes of calculating growth in CY1, Amgen will
     compare the [*]. For purposes of calculating growth in CY2, Amgen will
     compare the [*]. Aggregated Qualified Purchases of EPOGEN(R) for calendar
     year 2001 shall be calculated [*]. Total aggregate Qualified Purchases for
     CY1 and CY2 shall be calculated using [*]. [*]

4.   [*].

5.   [*] For the period beginning January 1, 2002 and ending March 31, 2002 NMC
     shall be eligible to receive a [*] if certain data elements are transmitted
     to Amgen [*]. Beginning April 1, 2002 through the remainder of the Term of
     the Agreement, the [*]. [*]

6.   [*].  NMC may qualify for [*] provided it meets the criteria described
     below:

     a.  CALCULATION:  NMC's [*] will be calculated in accordance with the
         following formula and with the [*] listed below:

                                           [*].
                                                 [*]

     For the purposes of calculating [*], Amgen will incorporate purchases of
     any newly created facility (but not facilities added through acquisition).
     [*].

     b.  VESTING: Notwithstanding  the foregoing,  NMC's [*] will vest annually
         on the [*], and will be paid in accordance with the terms and
         conditions described above.

7.   [*], NMC and Affiliates may qualify for a [*] provided it meets the
     criteria described below in this Section.  [*].

     a.  REQUIREMENTS: In order to qualify for [*], NMC must provide Amgen [*].

     b.  CALCULATION: Assuming NMC has fulfilled  all requirements as described
         in Section 7(a) above,  the [*] for NMC will be calculated as follows:

         [*].

     c.  PAYMENT: The [*] will be calculated on a [*] basis and paid to NMC's
         corporate  headquarters, except as otherwise provided hereunder.  [*].

     d.  VESTING: Notwithstanding the foregoing, NMC's [*] will vest annually
         on [*], and will be paid in accordance  with the terms and conditions
         described above.

                                     - 5 -

<PAGE>

                     FREESTANDING DIALYSIS CENTER AGREEMENT
--------------------------------------------------------------------------------

               APPENDIX B: LIST OF NMC SUBSIDIARIES AND AFFILIATES

                                  SUBSIDIARIES:

       Bio-Medical Applications Management Co., Inc. and its subsidiaries

                         Dialysis America, Georgia, LLC.

                                   Erika, Inc.

                   Integrated Renal Care of the Pacific, LLC.

                               Infusion Care, Inc.

                  National Medical Care HomeCare Division, Inc.

                         Renal Research Institute, LLC.

                 SRC Holding Company, Inc. and its subsidiaries

             Everest Healthcare Holdings, Inc. and its subsidiaries

                           Extracorporeal Alliance/CVR

                 Fresenius Medical Care Pharmacy Services, Inc.

                                   AFFILIATES:

                           See Contract List Attached

                                     - 6 -

<PAGE>
                     FREESTANDING DIALYSIS CENTER AGREEMENT
--------------------------------------------------------------------------------

                 APPENDIX C: LIST OF NMC AUTHORIZED WHOLESALERS

      TO ENSURE YOU RECEIVE THE APPROPRIATE DISCOUNT, IT IS IMPORTANT THAT WE
HAVE YOUR CURRENT LIST OF AUTHORIZED WHOLESALERS. THE FOLLOWING LIST REPRESENTS
THE WHOLESALERS AMGEN CURRENTLY HAS ASSOCIATED WITH YOUR CONTRACT. PLEASE UPDATE
THE LIST BY ADDING OR DELETING WHOLESALERS AS NECESSARY.

Bergen Brunswig Corporation
4000 Metropolitan Drive
Orange, CA  92668

J.M. Blanco Inc.
Calle D - Lote No. 21
Guaynabo, PR 00965

Metro Medical Supply, Inc.
3332 Powell Avenue
Nashville, TN 37204

Bellco Drug Corporation
101 East Hoffman Avenue
Lindenhurst, NY 11757

                                     - 7 -
<PAGE>

                     FREESTANDING DIALYSIS CENTER AGREEMENT
--------------------------------------------------------------------------------

                APPENDIX D: TERMS FOR PURCHASE OF DIRECT PRODUCT

Pursuant to Section 19 of the Agreement, the terms under which NMC may purchase
Products on a direct basis from Amgen are as follows:

1.   ORDERS/INVOICES. NMC will transmit orders and receive corresponding
     invoices via electronic data interchange ("EDI") in

     Orders may be submitted via facsimile, mail, or telephone to the address
     and telephone/fax numbers listed below. [*].

     [*].

     Amgen Customer Service may be reached at the following address and phone
     numbers:

                 Amgen USA Inc.

                 CUSTOMER SERVICE DEPARTMENT         FAX 1-800-292-6436
                 One Amgen Center Drive              Tel: 1-800-282-6436
                 Thousand Oaks, CA 91320-1799

2.   SHIPPING, TRANSPORTATION AND CHARGES.  [*].

3.   TITLE AND RISK OF LOSS.  [*].

4.   PRICING FOR DIRECT PRODUCT. NMC may purchase Direct Product from Amgen on
     a direct basis in accordance with Appendix A of the Agreement.

5.   TERMS OF PAYMENT.  NMC agrees to pay for Direct Product ordered, at
     terms of [*].

                                     - 8 -
<PAGE>

                     FREESTANDING DIALYSIS CENTER AGREEMENT
--------------------------------------------------------------------------------

                APPENDIX E: LIST OF APPROVED DISTRIBUTION CENTERS

Fresenius USA Manufacturing, Inc.
d/b/a Nephromed and affiliates
95 Hayden Avenue
Lexington, MA  92420-9192

                                     - 9 -
<PAGE>
                     FREESTANDING DIALYSIS CENTER AGREEMENT
--------------------------------------------------------------------------------

                                                                      EXHIBIT #1

                           SAMPLE CERTIFICATION LETTER

Month X, 2002

FSDC Legal Name
Street Address
City, ST  Zip

RE:  Agreement No. _________________

Dear ____________:

Thank you for your participation in the [*] Incentive Program. In order for us
to enroll you, we require that a duly authorized representative of your
organization sign the certification below.

Upon receipt of this executed document, we will calculate the value of your
incentive. If we do not receive the executed certification, we cannot provide
you with this incentive.

If you have any questions regarding this letter please contact me at [*]. Thank
you for your assistance in returning this certification.

Sincerely,

[*]

CERTIFICATION:

On behalf of FSDC Legal Name and all eligible Affiliates participating in the
[*] Incentive Program under Agreement No. __________ , the undersigned hereby
certifies that the [*] data submitted for each eligible Affiliate includes the
required [*] results from all dialysis patients of such Affiliate, and does not
include [*] results from non-patients. The party executing this document also
represents and warrants that it (i) has no reason to believe that the submitted
[*] data is incorrect, and (ii) is authorized to make this certification on
behalf of all eligible Affiliates submitting [*] data.

FSDC LEGAL NAME

Signature:            _____________________________

Print Name:           _____________________________

Print Title:          _____________________________

Date:                 _____________________________

                                     - 10 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00039-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00039-of-00352.parquet"}]]